Skip to content
Home/Companies/Biotech/Forendo Pharma

Forendo Pharma

Biotech·Finland·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Forendo Pharma?

Forendo Pharma is a Finnish Biotech company, now owned by Organon, which acquired it in 2021 from Sunstone Life Science Ventures.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures IV · 2015 · VC

Key facts

HQFinland
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Organon
Exit Year
2021

More from Sunstone Life Science Ventures IV

Other portfolio companies in the same fund.

Oblique Therapeutics
Active
BiotechSweden· 2020
Synendos Therapeutics
Synendos Therapeutics
Active
BiotechSwitzerland· 2020
STipe Therapeutics
Exited 2024
BiotechDenmark· 2019
Symphogen
Exited 2020
BiotechDenmark· 2019
to Servier
OxThera
OxThera
Active
BiotechSweden· 2016
IO Biotech
IO Biotech
Exited 2021
BiotechDenmark· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Forendo Pharma?

Forendo Pharma is now owned by Organon, which acquired it in 2021 from Sunstone Life Science Ventures.

When did Organon acquire Forendo Pharma?

Organon acquired Forendo Pharma in 2021, buying from Sunstone Life Science Ventures.

Who did Forendo Pharma sell to?

Sunstone Life Science Ventures sold Forendo Pharma to Organon in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue